---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-019773"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:11:01.082825+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FDA clears IND for Telomir-Zn in advanced triple-negative breast cancer; Phase 1/2 trial planned for 1H 2026

## Summary
- FDA cleared IND for lead candidate Telomir-Zn in advanced/metastatic triple-negative breast cancer.
- Phase 1/2 trial to enroll ~76 patients; Phase 1 dose-escalation, Phase 2 primary endpoint ORR.
- Planned initiation in first half of 2026 at a leading US academic medical center.
- Preclinical data included pharmacology, toxicology, PK, and biomarker analyses.
- Translational biomarker program to assess epigenetic modulation and telomere dynamics.

## SEC filing metadata
- accession: 0001493152-26-019773
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315226019773/0001493152-26-019773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315226019773/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-019773
- JSON: https://secwatch.observer/filing/0001493152-26-019773.json
- Plain text: https://secwatch.observer/filing/0001493152-26-019773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.